If another agency, similar to the FDA, were created to handle postmarketing surveillance of drugs, would we be able to avoid recalls?
You are here
P&T® Journal contents for January 2005
Health Care & Law
The authors present the example of a triptan case study to help formulary decision-makers evaluate the cost-effectiveness of drugs within a category.
Dr. Prescott reviews the use of azithromycin microspheres for acute exacerbation of chronic bronchitis; moxifloxacin for intra-abdominal infection; oseltamivir for reducing the risk of pneumonia; anidulafungin for HIV-negative patients with esophageal candidiasis; enfuvirtide; tipranavir and combination therapies for HIV infection; and peginterferon alfa-2a/ribavirin for HIV/hepatitis C co-infection.
The author summarizes the benefits of an extended-release niacin/statin combination to slow atherosclerosis; telmisartan for hypertensive patients with the metabolic syndrome; a glucose–insulin infusion for acute myocardial infarction; tilarginine; a nitrate/diuretic for African-Americans with heart failure; isotope versus vasodilator therapy; rimonabant for weight loss; atorvastatin to delay Alzheimer’s disease; and a new marker (Lp-PLA2) for coronary artery disease.
The authors discuss the factors that influence physician-investigators to prescribe study drugs sooner and more often than physicians who are not involved in clinical trials.